XOMA (Nasdaq:XOMA) really is a remarkable story in many ways. Few companies have survived so long, and raised capital so many times, and done so little with it. While the company has actually approached $100 million in reported sales, and not many biotechs do even that much, the company has never had any real success in the clinic and has basically strung along successive generations of investors on hype and hope. Now that the company is changing up management yet again, investors should be asking themselves if there is really a good reason to stick by a company that has floundered around for more than 20 years to no real purpose.

Investopedia Markets: Explore the best one-stop source for financial news, quotes, and insights.

A Change at the Top
XOMA announced Wednesday that it's CEO Steve Engle was bailing on the company. Engle said, "I am looking forward to applying my expertise building life science companies in the future."

Hmmm, expertise? Engle became XOMA's CEO in August of 2007. In the those four years, XOMA has gone from a market cap north of $350 million to a current market cap of just under $64 million, and the company really is not a great deal closer to having a winning product in its portfolio.

To be fair, though, Engle did oversee a licensing agreement with Servier that brought a $15 million upfront payment to the company (as well as $20 million more in loans and up to almost half a billion in potential milestones) for XOMA 052 - before the drug bombed in a Phase 2 diabetes study. What's more, Engle was in charge of the company when it monetized its royalty interest in CIMZIA and secured a contract from the National Institute of Allergy and Infectious Disease that could be worth $65 million for anti-botulinum products. Part and parcel of running a biotech is keeping money flowing into the enterprise and Engle was successful in that regard.

A Long History Of Disappointment
If or when XOMA 052 fails, it will be just another in a long line of XOMA setbacks. The company tried to be a player in monoclonal antibodies and had little to show for it - the company's attempts in sepsis failed and the psoriasis drug Raptiva was taken off the market by its partner due to exceptionally severe side-effects (including, ironically, sepsis). Along the way have been other failures in indications like cancer, acne and various autoimmune disorders.

What Now?
The trouble for XOMA shareholders today is that the company has little going for it in the clinic. The company thinks that XOMA 052 still has promise as an IL-1 antibody and gamely talks about a late stage clinical program for Behcet's uveitis and future opportunities in cardiovascular disease, gout and rheumatoid arthritis.

In fact, the company has offered up presentations before highlighting a $18 billion opportunity for IL-1 drugs, with about $7 billion of that from diabetes (now basically just theoretical given the failure of XOMA-052 in diabetes studies). And to be fair, XOMA 052 has shown a strong affinity for IL-1 beta and could be delivered in a convenient monthly dosing schedule.

The problem is, though, that there's just not any real evidence yet to support any of this. Regeneron (Nasdaq:REGN) has an approved IL-1 drug on the market (Arcalyst) and some three years after approval it's annualizing at about $20 million in sales. True, Arcalyst has a limited label and is a different drug, but there's no great clamor to use it off-label.

What's more, Servier is not exactly the strongest partner around and would likely struggle to market an equivocal drug effectively. XOMA has talked about targeting the market for myocardial infarction (a market where almost every biotech has failed) - and competing against the likes of Abbott Labs (NYSE:ABT) and Pfizer (NYSE:PFE) in autoimmune conditions like rheumatoid arthritis. That's a lot of ambition for a company with such a modest track record and an unspectacular partner.

The Bottom Line
Biotech companies like Isis (Nasdaq:ISIS), Vical (Nasdaq:VICL), and XOMA show that decades of disappointment and failure aren't the end of the story so long as they can sell a new generation of investors on their "promising blockbuster technology." To be fair, maybe Isis's mipomersen, Vical's Allovectin-7, or XOMA's XOMA 052 will finally be the winning products that propel the companies to the success that investors have been awaiting for decades.

During that same time period, though, investors could have gone with the likes of Cubist (Nasdaq:CBST), Alexion (Nasdaq:ALXN), Gilead (Nasdaq:GILD) or Celgene (Nasdaq:CELG) and had a great deal more to show for it. Every once in a while a biotech will snag victory from the jaws of long-term defeat, but one of the best predictors of the future in biotech is the past, and investors would do well to bring a healthy dose of skepticism with them to whatever XOMA's new management has to stay about the future of its pipeline. (For additional reading, take a look at A Primer On The Biotech Sector.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  3. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  4. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  6. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  7. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  8. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  9. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
  10. Professionals

    Tips for Helping Clients Though Market Corrections

    When the stock market sees a steep drop, clients are bound to get anxious. Here are some tips for talking them off the ledge.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!